WO2024190888A1 - Kit de polymérisation dentaire - Google Patents

Kit de polymérisation dentaire Download PDF

Info

Publication number
WO2024190888A1
WO2024190888A1 PCT/JP2024/010106 JP2024010106W WO2024190888A1 WO 2024190888 A1 WO2024190888 A1 WO 2024190888A1 JP 2024010106 W JP2024010106 W JP 2024010106W WO 2024190888 A1 WO2024190888 A1 WO 2024190888A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
mass
compound
group
examples
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2024/010106
Other languages
English (en)
Japanese (ja)
Inventor
勇介 山田
宜久 紙本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Medical Co Ltd
Original Assignee
Sun Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Medical Co Ltd filed Critical Sun Medical Co Ltd
Priority to JP2025507163A priority Critical patent/JPWO2024190888A1/ja
Publication of WO2024190888A1 publication Critical patent/WO2024190888A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/30—Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
    • A61K6/62—Photochemical radical initiators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/70—Preparations for dentistry comprising inorganic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/70—Preparations for dentistry comprising inorganic additives
    • A61K6/71—Fillers
    • A61K6/76—Fillers comprising silicon-containing compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/70—Preparations for dentistry comprising inorganic additives
    • A61K6/71—Fillers
    • A61K6/77—Glass

Definitions

  • the present invention relates to a dental polymerization kit.
  • a dental hardenable composition in a separate package type consisting of a first agent and a second agent has been proposed as a dental hardenable composition.
  • the first agent contains an acidic group-containing polymerizable monomer, a peroxyester, and a copper compound.
  • the second agent contains an aromatic sulfinate salt, and a benzotriazole compound or a benzimidazole compound (see, for example, Patent Document 1).
  • the present invention provides a dental polymerization kit that can improve the storage stability of each of Agent A and Agent B while ensuring an appropriate hardening time for the mixture of Agent A and Agent B and sufficient adhesive strength of the hardened product to tooth structure.
  • the present invention includes a dental polymerization kit comprising an acidic monomer having an acidic group and an ethylenically unsaturated group, an agent A containing an organic peroxide, and an agent B containing a reducing agent, and at least one of the agents A and B containing a specific benzimidazole compound represented by the following general formula:
  • R1 represents an aliphatic group, an aromatic group, an amino group, or a hydroxy group.
  • R2 represents an amino group, a hydroxy group, an aliphatic group, or an aromatic group.
  • R3 represents an aliphatic group, an aromatic group, an amino group, a hydroxy group, a halogen atom, or a hydrogen atom.
  • n is 0 or an integer of 1 to 4.
  • the present invention [3] includes the dental polymerization kit of [1] or [2] above, in which at least one of the agent A and the agent B contains the non-acidic monomer.
  • the present invention [4] includes any one of the dental polymerization kits [1] to [3] above, in which both agent A and agent B are in the form of a paste.
  • the present invention [5] includes any one of the dental polymerization kits [1] to [4] above, in which both the agent A and the agent B contain a filler.
  • the present invention [6] includes any one of the dental polymerization kits [1] to [5] above, in which the agent B further contains a transition metal compound.
  • the present invention [7] includes the dental polymerization kit of the above [6], in which the transition metal compound contains a transition metal atom belonging to the fourth period of the periodic table.
  • the present invention [8] includes the dental polymerization kit of the above [6] or [7], in which the transition metal compound is at least one of a copper compound, an iron compound, a cobalt compound, a chromium compound, a zinc compound, a manganese compound, and a vanadium compound.
  • the present invention includes any one of the dental polymerization kits [6] to [8] above, in which the transition metal compound is solid in the agent B, and when the agent A and the agent B are mixed, at least a portion of the transition metal compound is soluble in the acidic monomer in the agent A.
  • the present invention [10] includes the dental polymerization kit of the above [9], in which the transition metal compound is at least one of a copper compound, an iron compound, and a vanadium compound.
  • the present invention [11] includes any one of the dental polymerization kits [1] to [10] above, in which the agent A contains an inorganic peroxide.
  • the present invention [12] includes any one of the dental polymerization kits [1] to [11] above, in which the agent A contains a photopolymerization initiator.
  • the dental polymerization kit of the present invention can improve the storage stability of each of Agent A and Agent B while ensuring an appropriate hardening time for the mixture of Agent A and Agent B and sufficient adhesive strength of the hardened product to tooth structure.
  • Two-component self-adhesive resin cement which is an example of a dental polymerization kit, is used in dental treatment, for example, to bond a prosthesis to a missing tooth site.
  • the two-component self-adhesive resin cement comprises component A and component B.
  • the two-component self-adhesive resin cement is used, for example, by mixing components A and B immediately before use and applying the resulting mixture.
  • the two-component self-adhesive resin cement is also used, for example, by applying component A and then component B.
  • “Self-adhesive” means that the pretreatment agent has sufficient adhesion to the tooth structure even without being applied to the tooth structure.
  • Agent A contains an acidic monomer, an organic peroxide, and a specific benzimidazole compound. Agent A contains a polymerization accelerator, a non-acidic monomer, a filler, an inorganic peroxide, and a photopolymerization initiator as necessary. In addition, when agent B does not contain a non-acidic monomer and a filler, agent A necessarily contains a non-acidic monomer and a filler. Agent A does not contain a tertiary amine and a reducing agent. In this embodiment, agent A is liquid or paste.
  • the acidic monomer has an acidic group and an ethylenically unsaturated group.
  • acidic groups include carboxy groups, phosphate groups, thiophosphate groups, and sulfo groups.
  • the acidic monomer may contain only one type of acidic group, or may contain two or more types of acidic groups.
  • ethylenically unsaturated groups examples include acryloyl groups, methacryloyl groups, and vinyl groups.
  • acidic monomers having a carboxy group examples include aromatic carboxylic acid derivatives, aliphatic carboxylic acid derivatives, and amino acid derivatives.
  • aromatic carboxylic acid derivatives examples include benzoic acid derivatives, salicylic acid derivatives, phthalic acid derivatives, trimellitic acid derivatives, pyromellitic acid derivatives, naphthalene tricarboxylic acid derivatives, benzophenone tetracarboxylic acid derivatives, and biphenyl tetracarboxylic acid derivatives.
  • benzoic acid derivatives include 4-vinylbenzoic acid, 2-(meth)acryloyloxybenzoic acid, 3-(meth)acryloyloxybenzoic acid, 4-(meth)acryloyloxybenzoic acid, N-(meth)acryloyl-4-aminobenzoic acid, and N-(meth)acryloyl-5-aminobenzoic acid.
  • salicylic acid derivatives include 4-(meth)acryloylaminosalicylic acid and 5-(meth)acryloylaminosalicylic acid.
  • phthalic acid derivatives include 4-[(2-hydroxy-3-(meth)acryloyloxypropyl)amino]phthalic acid, 3-[N-methyl-N-(2-hydroxy-3-(meth)acryloyloxypropyl)amino]phthalic acid, and 4-[N-methyl-N-(2-hydroxy-3-(meth)acryloyloxypropyl)amino]phthalic acid.
  • trimellitic acid derivatives include 4-(meth)acryloyloxyalkyl trimellitic acid, 4-[2-hydroxy-3-(meth)acryloyloxy]butyl trimellitic acid, 2,3-bis(3,4-dicarboxybenzoyloxy)propyl(meth)acrylate, and 2-(3,4-dicarboxybenzoyloxy)-1,3-di(meth)acryloyloxypropane.
  • 4-(meth)acryloyloxyalkyl trimellitic acid include 4-(meth)acryloyloxymethyl trimellitic acid, 4-(meth)acryloyloxyethyl trimellitic acid, and 4-(meth)acryloyloxybutyl trimellitic acid.
  • pyromellitic acid derivatives include 1,4-di(meth)acryloyloxyethyl pyromellitic acid and the reaction product of 2-hydroxyethyl(meth)acrylate and pyromellitic acid dianhydride.
  • naphthalene tricarboxylic acid derivative is 6-(meth)acryloyloxyethylnaphthalene-1,2,6-tricarboxylic acid.
  • benzophenonetetracarboxylic acid derivative is the reaction product of 2-hydroxyethyl (meth)acrylate and 3,3',4,4'-benzophenonetetracarboxylic dianhydride.
  • biphenyltetracarboxylic acid derivative is the reaction product of 2-hydroxyethyl (meth)acrylate and 3,3',4,4'-biphenyltetracarboxylic dianhydride.
  • aliphatic carboxylic acid derivatives include maleic acid, a reaction product of 2-hydroxyethyl (meth)acrylate and maleic anhydride, and 11-(meth)acryloyloxy-1,1-undecanedicarboxylic acid.
  • amino acid derivatives include N,O-di(meth)acryloyloxytyrosine, O-(meth)acryloyloxytyrosine, N-(meth)acryloyloxytyrosine, N-(meth)acryloyloxyphenylalanine, a reaction product of N-phenylglycine with glycidyl (meth)acrylate, and a reaction product of N-tolylglycine with glycidyl (meth)acrylate.
  • the acidic monomer having a carboxy group is preferably an aromatic carboxylic acid derivative, more preferably a trimellitic acid derivative, more preferably 4-(meth)acryloyloxyalkyl trimellitic acid, more preferably 4-(meth)acryloyloxyethyl trimellitic acid, more preferably 4-methacryloyloxyethyl trimellitic acid.
  • acidic monomers having a phosphate group examples include aliphatic phosphate esters and aromatic phosphate esters.
  • aliphatic phosphate esters examples include (meth)acryloyloxyalkyl acid phosphate and bis[(meth)acryloyloxyalkyl] acid phosphate.
  • Examples of (meth)acryloyloxyalkyl acid phosphates include 2-(meth)acryloyloxyethyl acid phosphate, 2-(meth)acryloyloxypropyl acid phosphate, 3-(meth)acryloyloxypropyl acid phosphate, 4-(meth)acryloyloxybutyl acid phosphate, 6-(meth)acryloyloxyhexyl acid phosphate, 8-(meth)acryloyloxyoctyl acid phosphate, 10-(meth)acryloyloxydecyl acid phosphate, and 12-(meth)acryloyloxydodecyl acid phosphate.
  • bis[(meth)acryloyloxyalkyl] acid phosphates include bis[2-(meth)acryloyloxyethyl] acid phosphate, bis[2-(meth)acryloyloxypropyl] acid phosphate, and bis[3-(meth)acryloyloxypropyl] acid phosphate.
  • aromatic phosphate esters examples include 2-(meth)acryloyloxyethyl phenyl acid phosphate and 2-(meth)acryloyloxyethyl-p-methoxyphenyl acid phosphate.
  • the acidic monomer having a phosphoric acid group is preferably an aliphatic phosphoric acid ester, more preferably (meth)acryloyloxyalkyl acid phosphate, more preferably 10-(meth)acryloyloxydecyl acid phosphate, more preferably 10-methacryloyloxydecyl acid phosphate (MDP).
  • MDP 10-methacryloyloxydecyl acid phosphate
  • acidic monomers having a thiophosphate group examples include compounds in which the phosphate group of the acidic monomers having a phosphate group described above is replaced with a thiophosphate group.
  • a preferred example of the acidic monomer is an acidic monomer having a phosphate group.
  • Acidic monomers can be used alone or in combination of two or more types.
  • the proportion of acidic monomers in agent A is, for example, 0.1% by mass or more, preferably 0.2% by mass or more, more preferably 0.5% by mass or more, and for example, 50% by mass or less, preferably 30% by mass or less, more preferably 20% by mass or less.
  • the ratio of the acidic monomer to the total amount of the non-acidic monomers in agent A and agent B is, for example, 1 part by mass or more, preferably 2 parts by mass or more, more preferably 5 parts by mass or more, and for example, 50 parts by mass or less, preferably 30 parts by mass or less, more preferably 20 parts by mass or less.
  • organic peroxides examples include diacyl peroxides, peroxy esters, dialkyl peroxides, peroxy ketals, ketone peroxides, and hydroperoxides.
  • Diacyl peroxides include, for example, benzoyl peroxide, diacetyl peroxide, 2,4-dichlorobenzoyl peroxide, decanoyl peroxide, 3,3,5-trimethylhexanoyl peroxide, lauroyl peroxide, and m-toluoyl peroxide.
  • peroxyesters examples include t-butylperoxybenzoate, bis-t-butylperoxyisophthalate, 2,5-dimethyl-2,5-bis(benzoylperoxy)hexane, t-butylperoxy-2-ethylhexanoate, and t-butylperoxyisopropyl carbonate.
  • dialkyl peroxides examples include dicumyl peroxide, di-t-butyl peroxide, 1,3-bis(t-butylperoxyisopropyl)benzene, and 2,5-dimethyl-2,5-di(t-butylperoxy)-3-hexane.
  • peroxyketals examples include 1,1-bis(t-butylperoxy)-3,3,5-trimethylcyclohexane, 1,1-bis(t-butylperoxy)cyclohexane, 2,2-bis(t-butylperoxy)butane, 2,2-bis(t-butylperoxy)octane, and 4,4-bis(t-butylperoxy)valeric acid-n-butyl ester.
  • ketone peroxide is methyl ethyl ketone peroxide.
  • hydroperoxides examples include cumene hydroperoxide, t-butyl hydroperoxide, t-amyl hydroperoxide, p-diisopropylbenzene hydroperoxide, 1,1,3,3-tetramethylbutyl hydroperoxide, and p-methane hydroperoxide.
  • organic peroxide preferably, peroxyester is used, and more preferably, t-butyl peroxybenzoate (BPB) is used.
  • peroxyester preferably, peroxyester is used, and more preferably, t-butyl peroxybenzoate (BPB) is used.
  • BPB t-butyl peroxybenzoate
  • Organic peroxides can be used alone or in combination of two or more types.
  • the proportion of organic peroxide in agent A is, for example, 0.05% by mass or more, preferably 0.1% by mass or more, and for example, 1% by mass or less, preferably 0.5% by mass or less.
  • the ratio of the organic peroxide relative to 100 parts by mass of the total amount of the acidic monomer in agent A and the non-acidic monomer in agent A or agent B is, for example, 0.01 parts by mass or more, preferably 0.1 parts by mass or more, and for example, 3 parts by mass or less, preferably 1 part by mass or less.
  • the specific benzimidazole compound is a compound in which the hydrogen atoms at positions 1 and 2 of benzimidazole are substituted with substituents.
  • the specific benzimidazole compound is represented by the following general formula:
  • R 1 represents an aliphatic group, an aromatic group, an amino group, or a hydroxy group.
  • Aliphatic groups include, for example, linear alkyl groups having 1 to 12 carbon atoms, or branched alkyl groups having 3 to 12 carbon atoms.
  • linear alkyl groups having 1 to 12 carbon atoms include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl groups.
  • Examples of branched alkyl groups having 3 to 12 carbon atoms include isopropyl, isobutyl, sec-butyl, tert-butyl, and 2-ethylhexyl groups.
  • aromatic groups include aromatic hydrocarbon groups and aromatic heterocyclic groups.
  • An example of an aromatic hydrocarbon group is a phenyl group.
  • aromatic heterocyclic groups include furyl, thienyl, pyrrolyl, pyridyl, and benzimidazolyl groups.
  • Hydrogen atoms in the aliphatic and aromatic groups may be substituted with halogen atoms, the aliphatic groups described above, or the aromatic groups described above.
  • Halogen atoms include, for example, fluorine, chlorine, bromine, and iodine.
  • An example of a substituted aliphatic group is a perfluoromethyl group.
  • An example of a substituted aromatic hydrocarbon group is the 4-bromophenyl group.
  • An example of a substituted aromatic heterocyclic group is the 2-n-propyl-4-methylbenzimidazol-6-yl group.
  • R2 represents an amino group, a hydroxy group, an aliphatic group, or an aromatic group.
  • the hydrogen atom in the amino group may be substituted with the above-mentioned aliphatic group or the above-mentioned aromatic group.
  • An example of a substituted amino group is a dimethylamino group.
  • Examples of the aliphatic group include the aliphatic groups described above.
  • Examples of the aromatic group include the aromatic groups described above.
  • R2 may be the same as R1 or may be different from R1 .
  • R3 represents an aliphatic group, an aromatic group, an amino group, a hydroxyl group, a halogen atom, or a hydrogen atom.
  • the aliphatic group include the aliphatic groups described above.
  • the aromatic group include the aromatic groups described above.
  • the halogen atom include the halogen atoms described above.
  • n is 0 or an integer from 1 to 4. Preferably, n is 0.
  • Preferred examples of specific benzimidazole compounds represented by the above general formula include 1,2-dimethylbenzimidazole, 2-amino-1-methylbenzimidazole, 2-(4-bromophenyl)-1-phenylbenzimidazole, and 2-(2-n-propyl-4-methylbenzimidazol-6-yl)-1-methylbenzimidazole.
  • Certain benzimidazole compounds can be used alone or in combination of two or more types.
  • the proportion of the specific benzimidazole compound in agent A is, for example, 0.1 mass% or more, preferably 0.2 mass% or more, more preferably 0.3 mass% or more, and for example, 7 mass% or less, preferably 5 mass% or less, more preferably 3 mass% or less.
  • the ratio of the specific benzimidazole compound to 100 parts by mass of the non-acidic monomer in agent A and agent B is, for example, 0.1 parts by mass or more, preferably 0.2 parts by mass or more, more preferably 0.3 parts by mass or more, and for example, 5 parts by mass or less, preferably 4 parts by mass or less, more preferably 3 parts by mass or less.
  • the ratio of the specific benzimidazole compound to 100 parts by mass of the transition metal compound is, for example, 100 parts by mass or more, preferably 200 parts by mass or more, and for example, 20,000 parts by mass or less, preferably 10,000 parts by mass or less.
  • the ratio of the specific benzimidazole compound to 100 parts by mass of the organic peroxide is, for example, 10 parts by mass or more, preferably 20 parts by mass or more, more preferably 30 parts by mass or more, and even more preferably 50 parts by mass or more, and is, for example, 700 parts by mass or less, preferably 500 parts by mass or less, and more preferably 400 parts by mass or less.
  • the polymerization accelerator is a specific imide compound represented by any one of the following general formulas (1) to (5).
  • General formula (1) represents saccharin, saccharin derivatives, and alkali metal salts thereof.
  • R represents a hydrogen atom, an alkali metal atom, an aliphatic group, or an aromatic group.
  • alkali metal atoms examples include lithium, potassium, and sodium.
  • Examples of the aliphatic group include the aliphatic groups listed above.
  • aromatic groups examples include the aromatic groups listed above.
  • Preferred examples of the specific imide compound represented by general formula (1) include saccharin, methylsaccharin (an example of a saccharin derivative), and sodium saccharin hydrate (an example of an alkali metal salt of saccharin).
  • General formula (2) shows a cyclic imide and an alkali metal salt thereof.
  • R1 shows a hydrogen atom, an alkali metal atom, an aliphatic group, or an aromatic group.
  • alkali metal atom include the above-mentioned alkali metal atoms.
  • aliphatic group include the above-mentioned aliphatic groups.
  • aromatic group include the above-mentioned aromatic groups.
  • R2 represents an alkylene group, an alkenylene group, or an arylene group.
  • alkylene groups examples include alkylene groups having 1 to 4 carbon atoms. Specific examples include methylene groups, ethylene groups, and propylene groups.
  • alkenylene groups include alkenylene groups having 1 to 4 carbon atoms. Specific examples include ethyleneylene groups.
  • An example of an arylene group is a phenylene group.
  • Hydrogen atoms in the alkylene group, alkenylene group, and arylene group may be substituted with the above-mentioned halogen atoms.
  • Preferred examples of the specific imide compound represented by general formula (2) include succinimide, glutarimide, and maleimide.
  • General formula (3) shows acyclic imides and their alkali metal salts.
  • R11 shows a hydrogen atom, an alkali metal atom, an aliphatic group, or an aromatic group.
  • alkali metal atom include the above-mentioned alkali metal atoms.
  • aliphatic group include the above-mentioned aliphatic groups.
  • aromatic group include the above-mentioned aromatic groups.
  • Each of R 12 and R 13 represents an aliphatic group or an aromatic group.
  • Examples of the aliphatic group include the aliphatic groups described above.
  • Examples of the aromatic group include the aromatic groups described above.
  • a preferred example of the specific imide compound represented by general formula (3) is diacetamide.
  • General formula (4) shows a cyclic sulfonimide and an alkali metal salt thereof.
  • R21 shows a hydrogen atom, an alkali metal atom, an aliphatic group, or an aromatic group.
  • the alkali metal atom include the above-mentioned alkali metal atom.
  • the aliphatic group include the above-mentioned aliphatic group.
  • the aromatic group include the above-mentioned aromatic group.
  • R22 represents an alkylene group, an alkenylene group, or an arylene group.
  • alkylene group include the alkylene group described above.
  • alkenylene group include the alkenylene group described above.
  • arylene group include the arylene group described above.
  • An example of a specific imide compound represented by general formula (4) is 4,4-difluoro-1,1,3,3-tetraoxide-1,3,2-dithiazetidine.
  • General formula (5) shows acyclic sulfonimide and its alkali metal salt.
  • R 31 shows a hydrogen atom, an alkali metal atom, an aliphatic group, or an aromatic group.
  • the alkali metal atom include the above-mentioned alkali metal atom.
  • the aliphatic group include the above-mentioned aliphatic group.
  • the aromatic group include the above-mentioned aromatic group.
  • Each of R 32 and R 33 represents an aliphatic group or an aromatic group.
  • Examples of the aliphatic group include the aliphatic groups described above.
  • Examples of the aromatic group include the aromatic groups described above.
  • Preferred examples of the specific imide compound represented by general formula (5) include dibenzenesulfonimide and N-phenylbis(trifluoromethanesulfonimide).
  • Polymerization accelerators can be used alone or in combination of two or more types.
  • the proportion of the polymerization accelerator in agent A is, for example, 0.05% by mass or more, preferably 0.1% by mass or more, and, for example, 5% by mass or less, preferably 3% by mass or less.
  • the ratio of the polymerization accelerator to 100 parts by mass of the acidic monomer is, for example, 5 parts by mass or more, preferably 10 parts by mass or more, and, for example, 25 parts by mass or less, preferably 20 parts by mass or less.
  • the ratio of the polymerization accelerator to 100 parts by mass of the tertiary amine in agent B is, for example, 10 parts by mass or more, preferably 15 parts by mass or more, more preferably 30 parts by mass or more, and for example, 400 parts by mass or less, preferably 350 parts by mass or less, more preferably 300 parts by mass or less.
  • Tertiary amines will be explained later.
  • Non-acidic Monomer does not have the above-mentioned acidic group, but has the above-mentioned ethylenically unsaturated group.
  • Non-acidic monomers are classified into those that have a hydroxyl group, those that have a urethane bond, and those that do not have a hydroxyl group or a urethane bond.
  • non-acidic monomers having a hydroxyl group examples include mono(meth)acrylates and di(meth)acrylates.
  • Examples of mono(meth)acrylates having a hydroxyl group include 2-hydroxyethyl(meth)acrylate, 3-hydroxypropyl(meth)acrylate, 6-hydroxyhexyl(meth)acrylate, and dihydroxypropyl mono(meth)acrylate.
  • Examples of mono(meth)acrylates having a hydroxyl group include 2-hydroxyethyl(meth)acrylate, and more preferably 2-hydroxyethyl methacrylate (HEMA).
  • An example of a di(meth)acrylate having a hydroxyl group is a bisphenol A derivative.
  • An example of a bisphenol A derivative having a hydroxyl group is 2,2-bis[4-(3-(meth)acryloyloxy-2-hydroxypropoxy)phenyl]propane.
  • UDMA UDMA
  • Examples of mono(meth)acrylates that do not have a hydroxyl group or a urethane bond include alkyl(meth)acrylates.
  • Examples of alkyl(meth)acrylates include methyl(meth)acrylate, ethyl(meth)acrylate, and butyl(meth)acrylate.
  • di(meth)acrylates that do not have hydroxyl groups or urethane bonds include alkanediol di(meth)acrylates, polyalkylene glycol di(meth)acrylates, and bisphenol A derivatives.
  • alkanediol di(meth)acrylate examples include ethylene glycol di(meth)acrylate, propylene glycol di(meth)acrylate, and neopentyl glycol di(meth)acrylate.
  • a preferred example of the alkanediol di(meth)acrylate is neopentyl glycol dimethacrylate (NPGDMA).
  • polyalkylene glycol di(meth)acrylates examples include diethylene glycol di(meth)acrylate, triethylene glycol di(meth)acrylate, polyethylene glycol di(meth)acrylate, and polypropylene glycol di(meth)acrylate.
  • a preferred example of the polyalkylene glycol di(meth)acrylate is triethylene glycol di(meth)acrylate (TEGDMA).
  • An example of a bisphenol A derivative that does not have a hydroxyl group or a urethane bond is ethoxylated bisphenol A dimethacrylate (EBPADMA).
  • Non-acidic monomers can be used alone or in combination of two or more types.
  • Agent A contains at least a non-acidic monomer having a hydroxyl group and a non-acidic monomer having a urethane bond among the non-acidic monomers described above.
  • the proportion of non-acidic monomers in agent A is, for example, 5% by mass or more, preferably 10% by mass or more, more preferably 15% by mass or more, and for example, 95% by mass or less, preferably 90% by mass or less, more preferably 85% by mass or less.
  • Examples of the filler include conventionally known fillers that can be used in dental materials. Specifically, examples of the filler include silica, silica alumina, alumina, alumina quartz, glass, titania, zirconia, and ytterbium fluoride. Examples of the silica include fumed silica. Examples of the glass include barium glass. The filler may be surface-treated with a coupling agent or the like to be hydrophobic or hydrophilic.
  • Fillers can be used alone or in combination of two or more types.
  • the proportion of the filler in agent A is, for example, 0.5% by mass or more, preferably 5% by mass or more, more preferably 15% by mass or more, and for example, 97% by mass or less, preferably 95% by mass or less, more preferably 90% by mass or less, more preferably 85% by mass or less, more preferably 75% by mass or less.
  • inorganic peroxides examples include persulfuric acid compounds, perphosphate compounds, perchloric acid compounds, and hydrogen peroxide derivatives.
  • persulfate compounds include sodium persulfate, potassium persulfate, calcium persulfate, magnesium persulfate, and ammonium persulfate.
  • perphosphate compounds include sodium perphosphate, potassium perphosphate, calcium perphosphate, magnesium perphosphate, and ammonium perphosphate.
  • perchlorate compounds include sodium perchlorate, potassium perchlorate, calcium perchlorate, magnesium perchlorate, and ammonium perchlorate.
  • hydrogen peroxide derivatives include hydrogen peroxide and urea peroxide.
  • the inorganic peroxide is a persulfate compound, more preferably, sodium persulfate or potassium persulfate.
  • Inorganic peroxides can be used alone or in combination of two or more types.
  • the proportion of inorganic peroxide in agent A is, for example, 0.01 mass% or more, preferably 0.05 mass% or more, more preferably 0.1 mass% or more, and for example, 10 mass% or less, preferably 7 mass% or less, more preferably 5 mass% or less.
  • the ratio of inorganic peroxide relative to 100 parts by mass of the total amount of the acidic monomer in agent A and the non-acidic monomer in agent A or agent B is, for example, 0.5 parts by mass or more, preferably 1 part by mass or more, and for example, 15 parts by mass or less, preferably 10 parts by mass or less.
  • Photopolymerization Initiator The photopolymerization initiator generates radicals when exposed to light.
  • photopolymerization initiators include (bis)acylphosphine oxides, ⁇ -diketones, ketals, thioxanthone derivatives, coumarin and its derivatives, and anthraquinone and its derivatives.
  • Examples of (bis)acylphosphine oxides include 2,4,6-trimethylbenzoyldiphenylphosphine oxide, 2,6-dimethoxybenzoyldiphenylphosphine oxide, 2,6-dichlorobenzoyldiphenylphosphine oxide, 2,4,6-trimethylbenzoylmethoxyphenylphosphine oxide, 2,4,6-trimethylbenzoylethoxyphenylphosphine oxide, and 2,3,5,6-tetramethylbenzoyldiphenylphosphine oxide.
  • Examples of ⁇ -diketones include camphorquinone.
  • Examples of ketals include benzyl dimethyl ketal and benzyl diethyl ketal.
  • Examples of thioxanthones include 2-chlorothioxanthone and 2,4-diethylthioxanthone.
  • Examples of coumarin and its derivatives include coumarin, 3,3'-carbonylbis(7-diethylaminocoumarin), 3-benzoyl-5,7-dimethoxycoumarin, 3-benzoyl-7-dimethylaminocoumarin, 3-carboxycoumarin, and 3-ethoxycarbonyl-6-methoxycoumarin.
  • anthraquinone and its derivatives examples include anthraquinone, 1-bromoanthraquinone, 1-chloroanthraquinone, 2-chloroanthraquinone, 1,2-benzanthraquinone, 1-methylanthraquinone, 2-ethylanthraquinone, and 1-hydroxyanthraquinone.
  • the photopolymerization initiator is preferably an ⁇ -diketone, more preferably camphorquinone (CQ).
  • Photopolymerization initiators can be used alone or in combination of two or more types.
  • the proportion of the photopolymerization initiator in agent A is, for example, 0.001% by mass or more, preferably 0.01% by mass or more, and for example, 1% by mass or less, preferably 0.1% by mass or less.
  • the ratio of the photopolymerization initiator relative to 100 parts by mass of the total amount of the acidic monomer in agent A and the non-acidic monomer in agent A or agent B is, for example, 0.01 parts by mass or more, preferably 0.05 parts by mass or more, and for example, 1 part by mass or less, preferably 0.5 parts by mass or less.
  • the agent A may contain a polymerization inhibitor, a thickener, a coupling agent, an ultraviolet absorber, a fluorescent agent, a pigment, and a solvent, as necessary.
  • a polymerization inhibitor is dibutylhydroxytoluene (BHT).
  • Agent B contains a reducing agent.
  • Agent B contains a transition metal compound, a non-acidic monomer, and a filler.
  • agent B necessarily contains a non-acidic monomer and a filler.
  • Agent B does not contain an acidic monomer, an organic peroxide, an inorganic peroxide, or a polymerization accelerator.
  • Agent B is in a liquid or paste form.
  • (2-1) Reducing Agent examples include tertiary amines, aromatic amino acids, sulfinic acids or salts thereof, thiourea compounds, phosphorous compounds, and sulfurous compounds.
  • Tertiary amines include, for example, aromatic tertiary amines.
  • aromatic tertiary amines examples include N,N-dialkyltoluidine, N,N-bis(hydroxyalkyl)toluidine, N,N-dialkylaniline, and dialkylaminobenzoic acid esters.
  • N,N-dialkyltoluidine examples include N,N-dimethyl-p-toluidine and N,N-diethyl-p-toluidine.
  • N,N-bis(hydroxyalkyl)toluidines examples include N,N-bis(2-hydroxyethyl)-p-toluidine (BHEPT) and N,N-bis(2-hydroxypropyl)-p-toluidine.
  • N,N-dialkylanilines examples include N,N-dimethylaniline and N,N-diethylaniline.
  • dialkylaminobenzoate esters examples include methyl 4-(dimethylamino)benzoate, ethyl 4-(dimethylamino)benzoate (EDAB), 2-butoxyethyl 4-(dimethylamino)benzoate, and isoamyl 4-(dimethylamino)benzoate.
  • aromatic amino acids examples include N-phenylglycinic acid, sodium N-phenylglycinate, and potassium N-phenylglycinate.
  • Sulfinic acids and their salts include, for example, aromatic sulfinic acids and their salts.
  • Aromatic sulfinic acids include, for example, benzenesulfinic acid, o-toluenesulfinic acid, p-toluenesulfinic acid, ethylbenzenesulfinic acid, decylbenzenesulfinic acid, dodecylbenzenesulfinic acid, chlorobenzenesulfinic acid, fluorobenzenesulfinic acid, and naphthalenesulfinic acid.
  • salts of aromatic sulfinic acid include lithium benzenesulfinate, sodium benzenesulfinate, potassium benzenesulfinate, magnesium benzenesulfinate, calcium benzenesulfinate, strontium benzenesulfinate, barium benzenesulfinate, butylamine salt of benzenesulfinic acid, aniline salt of benzenesulfinic acid, toluidine salt of benzenesulfinic acid, phenylenediamine salt of benzenesulfinic acid, diethylamine salt of benzenesulfinic acid, diphenylamine salt of benzenesulfinic acid, triethylamine salt of benzenesulfinic acid, tributylamine salt of benzenesulfinic acid, ammonium salt of benzenesulfinic acid, tetramethylbenzenesulfinic acid, etc.
  • ethylammonium trimethylbenzylammonium benzenesulfinate, lithium o-toluenesulfinate, sodium o-toluenesulfinate, potassium o-toluenesulfinate, calcium o-toluenesulfinate, cyclohexylamine salt of o-toluenesulfinate, aniline salt of o-toluenesulfinate, ammonium salt of o-toluenesulfinate, tetraethylammonium o-toluenesulfinate, lithium p-toluenesulfinate, sodium p-toluenesulfinate (STS), potassium p-toluenesulfinate, calcium p-toluenesulfinate, barium p-toluenesulfinate, ethylamine salt of p-toluenes
  • thiourea compounds for example, thiourea, methylthiourea, ethylthiourea, n-propylthiourea, isopropylthiourea, cyclohexylthiourea, benzylthiourea, phenylthiourea, acetylthiourea, benzoylthiourea, adamantylthiourea, (2-pyridyl)thiourea, 1-(2-tetrahydrofurfuryl)-2-thiourea, N,N'-dimethylthiourea, N,N'-diethylthiourea, N,N'-di-n-propylthiourea, N,N'-di-i
  • TMTU trimethylthiourea
  • Examples of phosphorous compounds include inorganic phosphorous compounds and organic phosphorous compounds.
  • inorganic phosphite compounds include calcium hypophosphite and sodium phosphite.
  • organic phosphite compounds include diethyl phosphite, dibutyl phosphite, diisopropyl phosphite, di-n-propyl phosphite, triphenyl phosphite, triallyl phosphite, diethyl phosphite, dibutyl phosphite, diisopropyl phosphite, di-n-propyl phosphite, triphenyl phosphite, and triallyl phosphite.
  • sulfurous acid compounds examples include inorganic sulfurous acid compounds and organic sulfurous acid compounds.
  • inorganic sulfite compounds include lithium sulfite, sodium sulfite, potassium sulfite, calcium sulfite, and sodium hydrogen sulfite.
  • organic sulfurous acid compounds examples include diethyl sulfite, di-n-propyl sulfite, diisopropyl sulfite, glycol sulfite, 1,3-propylene sulfite, and diallyl sulfite.
  • thiosulfate compounds include sodium thiosulfate, calcium thiosulfate, potassium thiosulfate, and magnesium thiosulfate.
  • Reducing agents can be used alone or in combination of two or more types.
  • the reducing agent is preferably a combination of a tertiary amine, a sulfinic acid or its salt, and a thiourea compound, more preferably a combination of an aromatic tertiary amine, an aromatic sulfinic acid or its salt, and an alkylthiourea, more preferably a combination of N,N-bis(hydroxyalkyl)toluidine, a dialkylaminobenzoic acid ester, p-toluenesulfinic acid or sodium p-toluenesulfinate, and a trialkylthiourea, and more preferably a combination of N,N-bis(2-hydroxyethyl)-p-toluidine, ethyl 4-(dimethylamino)benzoate, sodium p-toluenesulfinate, and trimethylthiourea.
  • the proportion of the reducing agent in agent B is, for example, 0.01% by mass or more, preferably 0.1% by mass or more, more preferably 0.5% by mass or more, and for example, 30% by mass or less, preferably 20% by mass or less, more preferably 10% by mass or less.
  • the proportion of tertiary amine in agent B is, for example, 0.1% by mass or more, preferably 0.5% by mass or more, and for example, 10% by mass or less, preferably 5% by mass or less.
  • the ratio of tertiary amine to 100 parts by mass of organic peroxide in agent A is, for example, 100 parts by mass or more, preferably 130 parts by mass or more, and for example, 200 parts by mass or less, preferably 170 parts by mass or less.
  • the ratio of the reducing agent (excluding tertiary amines) to 100 parts by mass of inorganic peroxide in agent A is, for example, 10 parts by mass or more, preferably 20 parts by mass or more, for example, 100 parts by mass or less, preferably 50 parts by mass or less.
  • the transition metal compound contains a transition metal atom belonging to the fourth period of the periodic table.
  • the periodic table is the IUPAC Periodic Table of the Elements (version date 1 December 2018).
  • transition metal atoms include scandium (Sc), titanium (Ti), vanadium (V), chromium (Cr), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn), and gallium (Ga).
  • transition metal atoms include titanium (Ti), vanadium (V), chromium (Cr), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), and zinc (Zn), and more preferred examples of transition metal atoms include vanadium (V), chromium (Cr), manganese (Mn), iron (Fe), cobalt (Co), nickel (Ni), copper (Cu), and zinc (Zn).
  • transition metal compounds include oxides, hydroxides, halides, carboxylates, sulfates, nitrates, carbonates, and complexes of transition metals.
  • halides include chlorides and bromides.
  • carboxylates include formates, acetates, oleates, acrylates, gluconates, phthalates, and citrates.
  • Transition metal complexes have a transition metal atom as the central metal and ligands that coordinate to the transition metal atom.
  • Examples of the ligands include diketone-based ligands, amine-based ligands, thiol-based ligands, urea-based ligands, and thiourea-based ligands.
  • Examples of the diketone-based ligands include acetylacetonate.
  • Examples of the amine-based ligands include alkanediamines, benzimidazole, and benzothiazole.
  • Examples of the thiol-based ligands include mercaptoethanol, mercaptotriazole, mercaptobenzothiazole, and mercaptobenzimidazole.
  • Examples of the urea-based ligands include urea and ethyleneurea.
  • Examples of the thiourea-based ligands include thiourea, acetylthiourea, pyridylthiourea, and ethylenethiourea.
  • transition metal compounds include copper compounds, iron compounds, cobalt compounds, chromium compounds, zinc compounds, manganese compounds, and vanadium compounds.
  • copper compounds include copper(II) hydroxide, copper(I) chloride, copper(II) chloride, copper(I) bromide, copper(II) bromide, copper(II) formate, copper(I) acetate, copper(II) acetate, copper(II) sulfate, copper(II) nitrate, copper(I) iodide, basic copper(II) carbonate, copper(I) oxide, copper(II) oxide, metallic copper, copper(II) oleate, copper(II) acrylate, copper(II) gluconate, copper(II) phthalate, copper(II) citrate, copper(II) acetylacetonate, mercaptobenzothiazole copper, 1,3-propanediamine copper, benzimidazole copper, benzothiazole copper, mercaptobenzimidazole copper (MBI-Cu), and copper thiourea.
  • iron compounds include iron(II) hydroxide, iron(III) oxide hydroxide, iron(II) chloride, iron(III) chloride, iron(I) bromide, iron(II) bromide, iron(II) acetate, iron(III) acetate, iron(II) carbonate, iron(II) oxide, iron(III) oxide, iron(II, III) oxide, metallic iron, iron(II) sulfate, iron(III) sulfate, iron(III) acetylacetonate, iron(III) citrate, and iron(II) gluconate.
  • cobalt compounds include cobalt(II) hydroxide, cobalt(II) chloride, cobalt(II) acetate, cobalt(II) bromide, basic cobalt carbonate, cobalt(II) sulfate, cobalt(II) oxide, cobalt(III) oxide, cobalt(II,III) oxide, metallic cobalt, cobalt(II) nitrate, and cobalt(III) acetylacetonate.
  • chromium compounds include chromium(III) acetate, chromium(II) chloride, chromium(III) chloride, chromium(IV) chloride, chromium(II) bromide, chromium(III) bromide, chromium(III) fluoride, chromium(V) fluoride, chromium(III) oxide, chromium(III) oxide, chromium(IV) oxide, chromium(VI) oxide, silver(I) chromate, chromium(III) nitrate, potassium dichromate, chromium(III) acetylacetonate, and chromium(III) hexafluoroacetylacetonate.
  • Examples of zinc compounds include zinc acetate, zinc chloride, zinc bromide, zinc iodide, zinc oxide, zinc sulfide, zinc nitrate, zinc sulfate, zinc phosphate, zinc diphosphate, zinc lactate, zinc salicylate, zinc stearate, zinc gluconate, zinc acrylate, and zinc 2-mercaptobenzothiazole.
  • manganese compounds include manganese(II) chloride, manganese(II) bromide, manganese(II) carbonate, manganese(II) fluoride, manganese(II) iodide, manganese(II) nitrate, manganese(IV) oxide, manganese(II) acetate, manganese(III) acetate, manganese(II) phosphate, manganese(II) sulfate, manganese(II) acetylacetonate, and manganese(III) acetylacetonate.
  • vanadium compounds include vanadium(III) chloride, vanadium(III) bromide, metallic vanadium, vanadium(II) oxide, vanadium(III) oxide, vanadium(V) oxide, vanadium(IV) oxyacetylacetonate, vanadium(III) acetylacetonate, oxovanadium(IV) oxalate, vanadium(IV) stearate oxide, vanadium(IV) oxide sulfate, ammonium vanadate(V), and sodium orthovanadate(V).
  • the transition metal compound is solid in agent B.
  • agent B contains the components in agent B and a water-insoluble transition metal compound powder that may be acquired by moisture absorption during storage.
  • the amount of the transition metal compound dissolved in 100 g of water at 20°C and 1 atm is, for example, 5 g or less, preferably 4 g or less, and more preferably 3 g or less.
  • the average particle size is, for example, 0.01 ⁇ m or more, preferably 0.1 ⁇ m or more, more preferably 1 ⁇ m or more, and, for example, 500 ⁇ m or less, preferably 100 ⁇ m or less, and more preferably 50 ⁇ m or less.
  • transition metal compound is a solid in component B, at least a portion of the transition metal compound is soluble in the acidic monomer in component A when components A and B are mixed.
  • the transition metal compound is preferably at least one of a copper compound, an iron compound, and a vanadium compound.
  • Transition metal compounds can be used alone or in combination of two or more types.
  • the proportion of the transition metal compound in agent B is, for example, 0.0001 mass% or more, preferably 0.0005 mass% or more, more preferably 0.001 mass% or more, and for example, 1 mass% or less, preferably 0.5 mass% or less, more preferably 0.3 mass% or less.
  • the ratio of the transition metal compound to 100 parts by mass of the reducing agent is, for example, 0.001 parts by mass or more, preferably 0.005 parts by mass or more, more preferably 0.01 parts by mass or more, and is, for example, 10 parts by mass or less, preferably 5 parts by mass or less, more preferably 3 parts by mass or less.
  • the ratio of the transition metal compound to 100 parts by mass of the inorganic peroxide in Agent A is, for example, 0.001 parts by mass or more, preferably 0.005 parts by mass or more, more preferably 0.01 parts by mass or more, and is, for example, 10 parts by mass or less, preferably 5 parts by mass or less, more preferably 3 parts by mass or less.
  • Non-acidic Monomers examples include the same monomers as the non-acidic monomers in the A component.
  • the proportion of non-acidic monomers in agent B is not limited.
  • the proportion of non-acidic monomers in agent B is, for example, 5% by mass or more, preferably 10% by mass or more, more preferably 15% by mass or more, and for example, 99% by mass or less, preferably 90% by mass or less, more preferably 85% by mass or less.
  • the proportion of the filler in agent B is, for example, 10% by mass or more, preferably 20% by mass or more, more preferably 30% by mass, and for example, 97% by mass or less, preferably 95% by mass or less, more preferably 90% by mass or less.
  • Additives Agent B may contain a polymerization inhibitor, a neutralizing agent, a thickening agent, a solvent, a coupling agent, an ultraviolet absorbing agent, a fluorescent agent, and a pigment, if necessary.
  • the explanations of the polymerization inhibitor, the thickening agent, the solvent, the coupling agent, the ultraviolet absorbing agent, the fluorescent agent, and the pigment in agent B are the same as those of the polymerization inhibitor, the thickening agent, the solvent, the coupling agent, the ultraviolet absorbing agent, the fluorescent agent, and the pigment in agent A.
  • An example of a neutralizing agent is calcium hydroxide.
  • a mixture of components A and B is applied to at least one of the tooth structure and the prosthesis to bond the two together.
  • radicals are generated by an oxidation-reduction reaction between the organic peroxide and inorganic peroxide and the reducing agent.
  • the transition metal compound reacts with the reducing agent, dissolved oxygen, polymerization accelerator, and oxidizing agent (organic peroxide and inorganic peroxide), generating radicals.
  • a specific benzimidazole compound coordinates with the transition metal compound, increasing the reaction activity of the transition metal compound and generating more radicals.
  • the generated radicals polymerize acidic and non-acidic monomers.
  • the dental polymerization kit is used to polymerize non-acidic monomers in dental treatment.
  • the mixture of components A and B hardens as the acidic and non-acidic monomers polymerize, bonding the prosthesis to the tooth structure.
  • At least one of the agent A containing an acidic monomer and an organic peroxide and the agent B containing a reducing agent contains a specific benzimidazole compound represented by the above general formula.
  • Agent A does not have to contain a specific benzimidazole compound.
  • Agent B contains a specific benzimidazole compound.
  • the dental polymerization kit may be a two-part dental self-adhesive composite resin.
  • the two-part dental self-adhesive composite resin is used in dental treatment, for example, to fill missing teeth.
  • the dental polymerization kit may be a two-component dental coating agent.
  • the two-component dental coating agent is used in dental treatment, for example, to coat the surface of tooth tissue.
  • Agent A and Agent B According to the formulations in Tables 1 to 5, for each of Agent A and Agent B, first, the monomer liquid components were mixed to prepare a monomer liquid, and then a dispersing component (a component that disperses in a solid state in the monomer liquid) was added to the monomer liquid and mixed with a centrifugal mixer. In this way, Agent A and Agent B in a paste form were prepared.
  • a dispersing component a component that disperses in a solid state in the monomer liquid
  • Agent A or B gelled or hardened during or immediately after preparation.
  • the curing time is more than 2 minutes but less than 5 minutes.
  • the curing time is less than 2 minutes or more than 5 minutes.
  • the curing time is less than 2 minutes, it will harden too quickly. If the curing time is more than 5 minutes, it will harden too slowly. If the curing time is more than 2 minutes but less than 5 minutes, it is suitable for dental treatment.
  • the tensile adhesive strength is 2 MPa or more.
  • the tensile adhesion strength is less than 2 MPa.
  • the dental polymerization kit of the present invention is used in dental treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Dental Preparations (AREA)

Abstract

Ce kit de polymérisation dentaire est utilisé en dentisterie afin de polymériser un monomère non acide qui est exempt de groupes acides mais qui comporte des groupes éthyléniquement insaturés. Le kit comprend : un agent A qui est une combinaison d'un monomère acide ayant des groupes acides et des groupes éthyléniquement insaturés et d'un peroxyde organique ; et un agent B qui contient un agent réducteur. L'agent A et/ou l'agent B contiennent un composé benzimidazole spécifique.
PCT/JP2024/010106 2023-03-16 2024-03-14 Kit de polymérisation dentaire Ceased WO2024190888A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025507163A JPWO2024190888A1 (fr) 2023-03-16 2024-03-14

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-042422 2023-03-16
JP2023042422 2023-03-16

Publications (1)

Publication Number Publication Date
WO2024190888A1 true WO2024190888A1 (fr) 2024-09-19

Family

ID=92755324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/010106 Ceased WO2024190888A1 (fr) 2023-03-16 2024-03-14 Kit de polymérisation dentaire

Country Status (2)

Country Link
JP (1) JPWO2024190888A1 (fr)
WO (1) WO2024190888A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326779A (en) * 1984-03-19 1994-07-05 The Rockefeller University Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles
JP2012503627A (ja) * 2008-09-25 2012-02-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗炎症剤としての１ｈ−ベンズイミダゾール−５−カルボキサミド
JP2013144658A (ja) * 2012-01-16 2013-07-25 Tokuyama Dental Corp 歯科用硬化性組成物
JP2022112496A (ja) * 2021-01-21 2022-08-02 イフォクレール ヴィヴァデント アクチェンゲゼルシャフト 一時的クラウンおよびブリッジを生成するための歯科用材料

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326779A (en) * 1984-03-19 1994-07-05 The Rockefeller University Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles
JP2012503627A (ja) * 2008-09-25 2012-02-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗炎症剤としての１ｈ−ベンズイミダゾール−５−カルボキサミド
JP2013144658A (ja) * 2012-01-16 2013-07-25 Tokuyama Dental Corp 歯科用硬化性組成物
JP2022112496A (ja) * 2021-01-21 2022-08-02 イフォクレール ヴィヴァデント アクチェンゲゼルシャフト 一時的クラウンおよびブリッジを生成するための歯科用材料

Also Published As

Publication number Publication date
JPWO2024190888A1 (fr) 2024-09-19

Similar Documents

Publication Publication Date Title
US4985516A (en) Curable composition
JP2634276B2 (ja) プライマー組成物
JP6461952B2 (ja) 歯科用セメント
JPH075680B2 (ja) 硬化性組成物
US11306160B2 (en) Curable composition
US5700875A (en) Adhesive composition for dental treatment
JP3443188B2 (ja) 硬化性組成物
WO2022014492A1 (fr) Initiateur de polymérisation, kit de préparation de composition durcissable, composition durcissable, produit durci et matériau dentaire
JP7417609B2 (ja) 抗菌ポリマー粒子を含む組成物
JP6900490B2 (ja) 分包型硬化性組成物
JP2962628B2 (ja) 歯質の接着性組成物および接着方法
WO2024190888A1 (fr) Kit de polymérisation dentaire
WO2022209944A1 (fr) Kit de polymérisation dentaire
WO2024190887A1 (fr) Kit de polymérisation dentaire
JP5063349B2 (ja) 歯科用硬化性組成物および該歯科用硬化性組成物用キット
JP2018002649A (ja) 歯科用重合性組成物
WO2022196757A1 (fr) Composition contenant un initiateur de polymérisation et composition polymérisable dentaire
JPS63162710A (ja) 硬化性組成物
JPH0588683B2 (fr)
JP2021116346A (ja) 重合開始剤、硬化性組成物調製用キット、硬化性組成物、硬化物及び歯科材料
JP2025152115A (ja) 歯科用重合性組成物
JP2025144360A (ja) 二剤型歯科用材料
JP2025028768A (ja) 歯科用接着剤
JPH0629164B2 (ja) 歯科用修復材組成物
JPS63111861A (ja) 歯科用接着性組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24770990

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2025507163

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 24770990

Country of ref document: EP

Kind code of ref document: A1